Proyectos

Código

101182922

Investigador/a principal

Jaume Mora Graupera

Rol

Participant

Año de inicio

2024

Año de finalización

2028

Import total

123350€

Objectius

Every year 16.000 children in Europe are diagnosed with cancer, and 2000 children (approximately 70 school classes) die from this illness. New therapeutic solutions are advancing rapidly however the optimization and implementation into clinical trials accessible for these children is lacking behind. New therapeutic interventions often don’t make it through the valley of death between preclinical development and clinical implementation. In addition, the accessibility between countries of new treatments varies largely. Therefore, the GRASSHOPPER consortium aims to create a multidisciplinary network of stakeholders in pediatric cancer development to boost implementation of new therapeutic interventions for children with cancer across Europe and beyond. GRASSHOPPER consists of 10 beneficiaries and 9 associated partners located in 15 countries: 7 academic European Comprehensive Childhood Cancer Centers (CCCC’s) and 3 non-European CCCC’s, 4 non-academic national leading Childhood Cancer Centers, 2 leading pharmaceutical companies, 1 non-for-profit drug developer and 2 European networks in Early Phase Clinical trials (ITCC) and adult and AYA cancer (Cancer Core Europe). The consortium has 4 objectives: identification and preclinical validation of new immune interventions (1) and new molecular interventions (2), stimulating repurposing of available therapeutic interventions (3) and improving clinical validation of high potential therapeutic interventions for pediatric cancer (4). These objectives will be achieved by
intersectoral secondments between the various beneficiaries and partners. The consortium expects that these objectives will lead to a strong international and multidisciplinary network, exchange of knowledge and expertise between sectors and countries and lead to highly skilled researchers, trained in pediatric and transferable skills, and with a large network for future career perspectives, that will jump over the valley of death and accelerate new treatments.

Código

CPP2023-010646

Investigador/a principal

Josep Rubio Palau

Rol

Participant

Año de inicio

2024

Año de finalización

2027

Import total

330922,59€

Objectius

The project focuses on solving a real clinical need by developing new SoHO (Substances of Human Origin) bioinks which would be a key raw material for bioprinting research and health research facilities. These SoHO bioinks will pave the way, for example, to improve the current approach to reconstructive surgeries using autologous cartilage grafting. Cartilage-based reconstructive surgeries are one of the most common fracture and plastic reconstructive surgical approaches in paediatrics and adult care (auricular and laryngotracheal reconstruction, rhinoplasty, etc). The current surgical approach has drawbacks, such as long surgery times, manual work of the surgeon in the operating room, as well as an increased risk of complications, and increased morbidity in the donor, longer postoperative care and hospital stays.
The 3DCartiBone project goal is to develop and validate new SoHO bioinks capable of being applied to a new procedure for the production of patient-specific osteochondral-like bioprinted grafts enriched with multipotent mesenchymal stromal cells (MSC). This would dramatically improve surgical approach by reducing the need for harvesting costal cartilage autografts, or cartilage allografts from human cadaveric donors, solving the risks and the problems related with the donor-receptor graft matching and reducing time of surgery, patient length of stay in post-surgical admission and clinical outcomes (patient recovery).
Novelty of the proposal relies on the development of bioinks based on substances of human origin (SoHO) to develop bioprinted osteochondral grafts in biomedical research facilities, helping the progress on TRL in order to accelerate future application on humans, which would carry all the benefits described in the previous paragraph. This approach will be performed through the modification of SoHO biopolymers to ensure human cell differentiation. For this purpose, the synthesis of new monomers able to be directly bonded to the macromolecule backbone maintaining the self-assembly ability to reproduce the biphasic interphase will be carried out. Thus, the modification of SoHO substances with these monomers will act as bioinks and cell-platforms (microcarriers) for the bio-printing of a new generation biphasic construct for cartilage graft. In addition to being one of the first works to use SoHO bioinks, the fact of combining them with biomolecular orientation strategies based on self-assembly allows to obtain scaffolds that will provide tissues with gradient properties.
The validation of the bioprinted osteochondral-like graft will be done in vitro to evaluate the biocompatibility, viability and cell proliferation and in vivo in a sheep animal model to evaluate its safety, integration and functionality.

Código

CPP2023-010887

Investigador/a principal

Martí Pons Òdena

Rol

Participant

Año de inicio

2024

Año de finalización

2027

Import total

138765€

Objectius

MINISTERIO DE CIENCIA E INNOVACIÓN_Marti Pons

Código

CPP2023-010986

Investigador/a principal

Judit López Luque

Rol

Participant

Año de inicio

2024

Año de finalización

2027

Import total

204418€

Objectius

MINISTERIO DE CIENCIA E INNOVACIÓN_Judit Lopez Luque

Código

SLT035/24/000066

Investigador/a principal

Lucía Peñarrubia San Florencio

Rol

Individual

Año de inicio

2024

Año de finalización

2026

Import total

75000€

Objectius

DEPARTAMENT DE SALUT_Lucía Peñarrubia

Código

101163781

Investigador/a principal

Begoña Nafria Escalera, Joana Claverol Torres

Rol

Participant

Año de inicio

2024

Año de finalización

2028

Import total

447576,25€

Objectius

Health systems face a time of unprecedented change, with spiralling costs, increasing cultural disparity in access to healthcare and research, and an infrastructure that is decades old. Today, telehealth is a realistic alternative making care and research more accessible and personalised with less burden to better support the most vulnerable in our society. The ability to test and monitor for illnesses using Patient Centric microSampling (PCmS) is at the centre of this reform. This proposal is designed to build upon existing pilots and knowledge, then collaborate cross-sectorially to co-create and test the logistics, infrastructure and tools required to make PCmS a core healthcare tool and an acceptable alternative to venous blood-draw across Europe. This project aligns with many IHI’s objectives focusing on cross-sectorial collaboration, emphasising patient and enduser- centric co-design of outputs, harmonised regulatory and data generation approaches enhancing the potential of digital innovations in healthcare, while aiming to reduce the environmental footprint during the project and in final outputs to ensure that the expected long-term impact is a reachable reality that will deliver significant benefit to the community and address unmet public health needs at scale.
Specifically the objectives are to:
1) Create an optimised ‘Gold Standard’ infrastructure and workflow for PCmS across Europe as a proven and reliable alternative to
venipuncture
2) Create a harmonised and clear regulatory and HTA pathways, standards and acceptability, measures and cost-benefit models
across Europe
3) Gather definitive evidence to draw a citable ‘line in the sand’ for future research to support decisions to integrate PCmS into
decentralised trials and care pathways
4) Foundation for future: Enable access to the developed PCmS scientific findings, tools and assessment

Investigador/a principal

Josep Maria Haro Abad, Roser Arnalte Olloquequi

Rol

Participant

Año de inicio

2024

Año de finalización

2026

Import total

138426,53€

Objectius

EUROPEAN COMMISSION_Josep Maria Haro

Código

101156595

Investigador/a principal

Cecilia Jiménez Mallebrera

Rol

Participant

Año de inicio

2024

Año de finalización

2031

Import total

141717,75€

Objectius

European Commission_Cecilia Jimenez

Código

RYC2022-035574-I

Investigador/a principal

Sandra Castillo Diez

Rol

Individual

Año de inicio

2024

Año de finalización

2029

Import total

244350€

Objectius

MINISTERIO DE CIENCIA E INNOVACIÓN_Sandra Castillo

Código

AEI-010500-2024-110

Investigador/a principal

Elena Codina Sampera

Rol

Participant

Año de inicio

2024

Año de finalización

2025

Import total

29894€

Objectius

Ministerio de Industria y Turismo_Codina Sampera, Elena